Early Percutaneous Tracheostomy for Cardiac Surgery (ETOC)

Assistance Publique - Hôpitaux de Paris212 enrolled

Overview

This is a phase III clinical trial comparing early tracheostomy (day 4) versus prolonged endotracheal intubation in ICU patients needing prolonged ventilatory support after cardiovascular surgery.

Background: Prolonged mechanical ventilation (MV\> 7 days) is required in less than 10% of patients after cardiovascular surgery but it is associated with high morbidity and mortality. Several studies conducted in critically ill patients suggested that early percutaneous tracheotomy compared with delayed tracheotomy decreases the length of ventilator dependence and improves outcome. To date, no randomized trial has tested these possible benefits in critically ill patients after cardiac surgery. Study objectives: A randomized trial has been designed to determine whether early tracheostomy (day 4 after cardiac surgery) in patients still on MV would reduce the number of days under MV, measured by the evaluation of ventilator-free days (VFDs). Secondary objectives are the reduction of mortality, reduction of ICU and hospital length of stay. Evaluation of organ failure evolution, infectious complications, sedation needs, patient comfort and outcome at 3 months will be also considered. Study hypothesis: The trial will be consider positive if early tracheotomy increases the number VFDs of at least 7 days (mean) evaluated on day 60 after randomisation. Methods : Trial : randomized, open, controlled, monocentric Inclusion criteria: see columns below Exclusion criteria: see columns below Randomization: will use a computerised system on day 4 after cardiac surgery Procedures: see columns below Recorded data: demographic characteristics, pre, per and postoperative parameters. From randomization until ICU discharge (or day 60), a daily chart will be completed. Judgment criteria: see columns below Sample size and statistical analysis: using Wilcoxon bilateral test with an alpha risk of 5% and a power of 80%, we calculated that 108 patients in each arm would be needed. Statistical analyses will use standard tests to compare population of the two arms.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

212

Conditions

Respiratory Failure Cardiovascular Surgery

Interventions

Dilatational Percutaneous tracheostomyPROCEDURE

Dilatational Percutaneous tracheostomy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Are 18 years of age or older * Have undergone cardiovascular surgery * Are still on invasive mechanical ventilation on day 4 after surgery * Have failed the screening test or the spontaneous breathing trial * Have signed the informed consent (patient or legal representative) Exclusion Criteria: * Age less than18 * Pregnant woman * Intubation more than 48 hours before cardiovascular surgery * More than 5 days on mechanical ventilation after cardiac surgery * Artificial heart implantation * Concomitant neck surgery (carotid) * Previously tracheostomized * Major hemorrhagic risk * Persistence of platelet count less than 50.000/mm3 after platelet transfusion * Prothrombin time less than 30% despite coagulation factors administration * Clinical evidence of ongoing infection at the proposed tracheotomy site * Anatomical deformity of the neck making risky a tracheostomy * Probability of dying the day of randomization defined by SAPSII more than 80 * Irreversible neurological lesions * Decision of care limitation * Prior inclusion in a trial with morbidity-mortality as main judgement criteria * Previous enrollment in this trial * Consent refusal

Locations (1)

Institut de Cardiologie - Chu Pitie Salpetriere Ap-Hp

Paris, France

Outcomes

Primary Outcomes

Number of ventilator-free days defined as the number of days between successful weaning from MV and day 60 after study enrolment.

Time frame: between successful weaning from MV and day 60 after study enrolment.

VFDs = 0 if the patient dies before 60days.

Time frame: before 60 days

VFDs= (60- X) : if the patient is successfully weaned from MV within 60 days, where X is the number of days spent receiving MV

Time frame: during 60 days

VFDs = 0: if the patient requires MV for 60 days or more

Time frame: during 60 days and after

The trial will be considered positive if early tracheostomy increases the number VFDs of at least 7 days (mean)

Time frame: at 7 days

Secondary Outcomes

Other outcomes will be compared between the two arms:

Time frame: during the trial

Mortality rate (day 60, in-ICU, in-hospital)

Time frame: during the 60 days

ICU length of stay

Time frame: during the trial

Hospital length of stay

Time frame: during the trial

Duration of MV in survivors

Time frame: during the trial

Organ failure evolution

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.